FWM
STOK icon

FFT Wealth Management’s Stoke Therapeutics STOK Stock Holding History

FFT Wealth Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-300
Closed -$10K – 220
2021
Q2 		$10K Buy
+300
New +$10.6K ﹤0.01% 232

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FFT Wealth Management's STOK Position: Q3 2021 in Review

FFT Wealth Management sold out of Stoke Therapeutics (STOK) in Q3 2021, closing a stake of 300 shares — an estimated $10K sold.

FFT Wealth Management first reported a position in STOK in Q2 2021 and held it in 1 quarter. The position peaked at $10K in Q2 2021. 90 funds tracked by Wall St. Rank hold STOK as of Q3 2021.

  • FFT Wealth Management reported no remaining Stoke Therapeutics position as of Q3 2021 after selling out during the quarter.
  • FFT Wealth Management sold 300 Stoke Therapeutics shares in Q3 2021, an estimated $10K.
  • FFT Wealth Management first reported a position in Stoke Therapeutics in Q2 2021 and held it in 1 quarter.
  • FFT Wealth Management's Stoke Therapeutics position peaked at $10K in Q2 2021.
  • 90 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2021.

Based on FFT Wealth Management's 13F filing for Q3 2021, filed 12 Nov 2021.